Latest news
PTCT: Record Q2 revenue and raised guidance reflect strong Sephience momentum and global expansion - TradingViewTradingView · Thu, 30 Jul 2026 23:12:42 GMTPTC Therapeutics 2Q 2026: Revenue $360.5M, EPS $0.92— 10-Q Summary - TradingViewTradingView · Thu, 30 Jul 2026 20:41:01 GMTPTC Therapeutics stock jumps 5% after topping Q2 estimates on strong Sephience sales - Investing.com AustraliaInvesting.com Australia · Thu, 30 Jul 2026 20:12:13 GMTPTCT: Sephience's launch and pipeline advances fuel rapid growth and global market leadership - TradingViewTradingView · Thu, 30 Jul 2026 07:00:00 GMTPTCT: Q2 2026 revenue surged 102% to $360.5M, led by Sephience and Novartis milestone payments - TradingViewTradingView · Thu, 30 Jul 2026 07:00:00 GMT